Close

Wastewater Management In Global Health & Disease Initiatives

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...
- Advertisement -

Wastewater management is increasingly recognized as a critical component in the surveillance and management of global health and diseases. With the interconnectedness of human, animal, and environmental health outlined by the One Health approach, the role of wastewater in monitoring and responding to public health threats has gained prominence. This document explores the evolution and effectiveness of wastewater-based epidemiology- WBE as a pivotal tool in disease surveillance systems, particularly highlighted during the COVID-19 pandemic.

The Crucial Role of Wastewater in Disease Surveillance

Wastewater, which includes a mixture of domestic, industrial, and agricultural effluents, is a reservoir for various pathogens, chemicals, and biological markers that reflect population health status. Analyzing these components has proven to be effective for early detection and monitoring when it comes to public health threats. The concept of one sample, many analyses in WBE enables comprehensive insights from minimal sampling, making it a cost-effective and efficient method in public health responses.

Impact of Wastewater on Environmental and Human Health

Human populations produce substantial amounts of wastewater, which contains a broad range of chemicals and biota, varying by the source. Sewage, a prevalent form of wastewater, is an inevitable consequence of concentrated human population centres. When sewage enters natural watercourses, it can severely impact environmental health by introducing pathogens and toxic compounds and fostering eutrophic conditions. Furthermore, sewage and other wastewater are sources of microplastics that contaminate aquatic environments, potentially impacting both environmental and human health. Untreated sewage, rich in micro-organisms, varies in range and diversity and poses significant health risks when introduced into natural habitats. These pathogens can directly affect environmental health and have downstream impacts on human health. Examples include the ingestion of faecally contaminated water through activities like swimming or the consumption of crops irrigated with such water.

Wastewater-Based Epidemiology- WBE as an Exemplar When It Comes To Disease Surveillance

The application of WBE in disease surveillance has gained significant recognition. Wastewater serves not only as a pollution source but also as a crucial public health information repository. High levels of pathogens and chemicals in faeces and urine, shed by infected individuals or those on medication, can be detected and quantified in sewage. This allows for community-wide disease surveillance in a relatively non-invasive manner and requires fewer samples to identify health patterns. Historically, WBE has been instrumental in detecting diseases like poliovirus in urban wastewater. During the COVID-19 pandemic, the scope of WBE expanded significantly, facilitating national and sub-national surveillance programs that monitored the emergence of pathogens and the effectiveness of interventions. Additionally, WBE has shown potential in tracking antimicrobial resistance and other endemic human pathogens, providing a comprehensive overview of public health threats. Its ability to detect a wide variety of biological and chemical markers makes it an invaluable tool in the One Health framework, supporting early warning systems and enhancing preparedness and response strategies in public health.

Global Implementation and Challenges of WBE

The global implementation of WBE has encountered challenges, including the need for advanced analytical technologies and substantial infrastructural investments. However, the potential of WBE in providing insights into public health dynamics makes it an invaluable component of the One Health approach. Enhanced sensitivity in detection methods, better data analytics platforms, and international cooperation are essential for standardizing surveillance practices and maximizing the benefits of WBE.

Tripartite and Quadripartite Agreements

On March 21, 2022, the World Organization for Animal Health- WOAH, Food and Agriculture Organization of the United Nations- FAO, World Health Organization- WHO, and UN Environment Program- UNEP signed a landmark quadripartite memorandum of understanding. This agreement aims to strengthen cooperation and optimize the health of humans, plants, animals, and the environment. This framework highlights antimicrobial resistance- AMR as a critical area of focus, demonstrating a global consensus on the need for a coordinated One Health response. AMR serves as a template for wider One Health initiatives, showcasing the importance of a collaborative, multi-sectoral approach to global health threats. These agreements facilitate knowledge sharing, technological advancements, and resource allocation, essential for the effective management of public health threats.

Case Studies in Wastewater Surveillance

Various case studies underscore the effectiveness of WBE in monitoring health threats. Regions utilizing WBE have successfully tracked antimicrobial resistance patterns, aiding global health responses. Moreover, WBE has demonstrated its capability to track the spread of specific pathogens, such as the SARS-CoV-2 variants, potentially reducing the need for equivalent surveillance in clinical samples. This approach provides a less invasive and more economical alternative to traditional disease surveillance methods. Additionally, WBE can be a crucial tool in understanding the prevalence of non-notifiable pathogens like norovirus, which significantly impact community health.

Future Directions and Opportunities

The future of WBE in global health surveillance is promising. Expanding its application to detect emerging zoonotic diseases and new pathogens can provide comprehensive insights into public health threats. The development of more sensitive analytical techniques will further enhance the utility of WBE, establishing it as a cornerstone of global health surveillance strategies. Collaboration among international health organizations and standardization of methodologies are crucial for the effective implementation of WBE across diverse regions.

Conclusive Thoughts

Wastewater management through WBE is a critical component of the One Health approach to global disease surveillance and management. By harnessing the comprehensive data derived from wastewater, health authorities can gain invaluable insights into population health dynamics, enabling informed decisions and effective interventions. As global health challenges evolve, the strategic enhancement of wastewater surveillance will be essential in safeguarding public health in an interconnected world. This detailed analysis not only underscores the importance of WBE in public health management but also highlights its potential to shape future health initiatives across the world.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »